Related references
Note: Only part of the references are listed.Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes
Dario Giugliano et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis
Takayuki Yamada et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
Suetonia C. Palmer et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P. H. Wilding et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020
DIABETES CARE (2020)
Obesity Management for the Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes-2020
DIABETES CARE (2020)
Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Clare Arnott et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map
Jianhong Zhu et al.
LANCET DIABETES & ENDOCRINOLOGY (2020)
Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment
Ignatios Ikonomidis et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The efficacy and safety of combinations of SGLT2 inhibitors and GLP-1 receptor agonists in the treatment of type 2 diabetes or obese adults: a systematic review and meta-analysis
Man Guo et al.
ENDOCRINE (2020)
Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes
Caroline K. Kramer et al.
ANNUAL REVIEW OF MEDICINE, VOL 70 (2019)
Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities
Emily Brown et al.
OBESITY REVIEWS (2019)
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial
Kenneth W. Mahaffey et al.
CIRCULATION (2019)
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Obesity and cardiovascular disease: revisiting an old relationship
Chrysi Koliaki et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis
Xiaoling Cai et al.
OBESITY (2018)
GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms
Manfredi Rizzo et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2018)
Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017
Thomas R. Einarson et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Adipokine dysregulation and adipose tissue inflammation in human obesity
Xabier Unamuno et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2018)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Adrian F. Hernandez et al.
LANCET (2018)
Dapagliflozin Binds Specifically to Sodium-Glucose Cotransporter 2 in the Proximal Renal Tubule
Chiara Ghezzi et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Comparison of exenatide and acarbose on intra-abdominal fat content in patients with obesity and type-2 diabetes: A randomized controlled trial
Li Shi et al.
OBESITY RESEARCH & CLINICAL PRACTICE (2017)
Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date
Francesca Cinti et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2017)
Obesity
Pedro Gonzalez-Muniesa et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms
Bart Staels
AMERICAN JOURNAL OF CARDIOLOGY (2017)
Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus
Kristy Iglay et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
F. Zaccardi et al.
DIABETES OBESITY & METABOLISM (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
Brian Hutton et al.
ANNALS OF INTERNAL MEDICINE (2015)
Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes The SCALE Diabetes Randomized Clinical Trial
Melanie J. Davies et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Incretin-Based Therapies, Glucometabolic Health and Endovascular Inflammation
Manfredi Rizzo et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors
John P. H. Wilding
METABOLISM-CLINICAL AND EXPERIMENTAL (2014)
SGLT inhibitors in management of diabetes
Abd A. Tahrani et al.
LANCET DIABETES & ENDOCRINOLOGY (2013)
Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?
Jiwen (Jim) Liu et al.
DIABETES (2012)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Enhanced expressions of sodium–glucose cotransporters in the kidneys of diabetic Zucker rats
Niloofar M. Tabatabai et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2008)
Share Paper
